Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medtronic Presents Durable Endeavor DES Results At ESC Meeting

This article was originally published in The Gray Sheet

Executive Summary

Medtronic's PMA for the Endeavor ABT-578-eluting stent will include data from over 2,800 patients, including three-year follow-up from the 100-patient ENDEAVOR-I trial

You may also be interested in...

Medtronic Spotlights Endeavor Stent Launch Abroad, ICDs Domestically

Medtronic believes it can capture more than 15% of the international drug-eluting stent market within one year of rolling out its Endeavor in 40 countries outside the U.S

Boston Scientific Counters J&J In “Perception Battle” With New Taxus Data

Boston Scientific expects new clinical trial data presented at the Paris Course on Revascularization (PCR) May 24 to help reverse an ongoing shift of the drug-eluting stent market toward Johnson & Johnson/Cordis

Post-Brexit MHRA Will Embrace Medtech ‘Innovation Pull’ In The UK

The national regulator is to undergo a review in 2021 as the UK begins life as a former EU member, presenting opportunities to be seized.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts